Aphaia Pharma is a clinical-stage biopharmaceutical company harnessing proprietary precision-targeted drug formulations to restore endogenous hormone release from nutrient-sensing cells in the gastrointestinal tract to treat and prevent metabolic disorders such as obesity and associated diseases. Aphaia’s lead drug candidate, an oral glucose formulation, has been shown to safely restore endogenous hormone release in individuals with obesity. It is being evaluated in two Phase 2 trials, one for chronic weight management in individuals with obesity and the second to improve glucose tolerance in individuals with prediabetes. The versatile design of Aphaia’s technology platform provides an opportunity for the development of treatments for multiple disease patterns.
Company Details
- Employees
- 9
- Founded
- -
- Address
- Bahnhofstraße 28, Zug,switzerland
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- aphaiapharma.com
- HQ
- Zug
Aphaia Pharma Questions
Aphaia Pharma's website is aphaiapharma.com
Aphaia Pharma's LinkedIn profile is https://ch.linkedin.com/company/aphaia-pharma
Aphaia Pharma has
9 employees.
View email and phone details for 9
employees at Aphaia Pharma.
Aphaia Pharma's industry is
Pharmaceutical Manufacturing
Aphaia Pharma's top competitors are
Bioventure Management,
Qanatpharma,
Terns Pharmaceuticals,
Abbvie,
Alpinamed Ag,
Perspective Therapeutics,
Adr-Ac Gmbh,
Quercis Pharma,
Alpen Pharma Ag,
Provirex Genome Editing Therapies Gmbh.
Aphaia Pharma's categories are Pharmaceutical Manufacturing
Aphaia Pharma's founding year is 2018
